; relative hazard for HIV DNA level, 2.73 per increase of 1 log 10 copies/10 6 PBMCs). Conclusions. Both a low initial CD4 cell count and a high HIV DNA level are predictive of rapid progression of untreated primary HIV-1 infection. Affected patients may therefore benefit from close clinical and laboratory monitoring and/or early administration of treatment.
The potential benefit of starting antiviral therapy during primary HIV infection is still controversial [1] [2] [3] [4] . Administration of combination antiretroviral therapy at this stage may reduce the initial spread of the virus through the body, attenuate T cell activation, and pre-serve HIV-specific immune responses [5] [6] [7] [8] [9] [10] [11] . Early treatment is also as efficient as later treatment with regard to viral replication, CD4 cell count, and progression to AIDS [12] [13] [14] . However, the benefits of treatment initiation during primary HIV infection have not yet been examined in a controlled clinical trial. Because of the toxicity and complexity of long-term antiretroviral regimens, treatment interruptions and suboptimal adherence to therapy are common [15] [16] [17] . In addition, viral rebound is common when the patient interrupts treatment that had been started during the acute phase of infection [18] . Recent guidelines state that therapy is optional for patients with ongoing acute infection and for those who had seroconversion !6 months earlier [19] [20] [21] .
In the French PRIMO Cohort, in which HIV-1-infected patients are recruited at the time of primary HIV infection, the proportion of initially untreated patients increased markedly from 1996 to 2004 [17] . This raises issues concerning the prognosis for such patients and the predictive value of initial immunological and virological parameters. Long-lasting and intense symptoms during primary HIV infection are associated with poorer subsequent outcomes, but unlike during the chronic phase of infection, it is less established whether virological and/or immunological factors during primary HIV infection are predictive of disease progression [22] [23] [24] .
Here, we describe the outcomes for patients enrolled in the prospective PRIMO Cohort who received a diagnosis of primary HIV-1 infection during the HAART era and who did not immediately begin taking antiretroviral treatment. We also report baseline factors predictive of subsequent clinical and immunological progression.
PATIENTS AND METHODS
The PRIMO Cohort. The ongoing multicenter French PRIMO Cohort enrolled 552 patients with primary HIV infection between November 1996 and October 2004. The median duration of follow-up of these patients is currently 30 months (interquartile range, 16-54 months). The PRIMO study protocol was approved by the Paris Cochin Ethics Committee. After giving their written informed consent, patients are enrolled if they had seroconversion to HIV-1 infection !6 months previously. Primary HIV infection is defined as "symptomatic" if at least 1 symptom associated with the acute HIV syndrome is present. Primary HIV infection is diagnosed on the basis of (1) an incomplete Western blot finding (i.e., absence of antip68 and anti-p34), (2) detection of plasma HIV RNA and a negative or weakly reactive ELISA result, or (3) an interval of !6 months between a negative and a positive ELISA result. The date of infection is estimated as the date of symptom onset minus 15 days, or, in asymptomatic patients, the date of the incomplete Western blot finding minus 1 month or the midpoint between a negative and a positive ELISA result [3] . Patients are treatment naive at enrollment, and the decision to begin antiretroviral therapy is left to the primary care physicians. Most treated patients start antiretroviral therapy at or soon after their enrollment visit. At enrollment, blood samples are collected for immunological and virological studies, and the patients undergo a physical examination. Clinical and laboratory investigations are done at months 1, 3, and 6 and every 6 months thereafter. HIV DNA levels in stored PBMCs are quantified at a central laboratory using a real-time PCR method with a quantification threshold of 70 copies/10 6 PBMCs [25, 26] .
Progression criteria. Analysis of disease progression was limited to patients who did not initiate treatment during the first 3 months after enrollment. Clinical progression was defined by the occurrence of death or an AIDS-defining event (on the basis of Centers for Disease Control and Prevention category C from 1993). Immunological progression was defined by the occurrence of a CD4 cell count !350 cells/mm 3 at or after the 3-month visit (because immunological fluctuations can occur during the acute phase of HIV infection). We chose this value because it represents the threshold at which treatment is generally indicated during both primary HIV infection and the chronic phase of infection.
Statistical analysis. Times to events were calculated by constructing Kaplan-Meier survival curves from the date of enrollment to the date of progression. For patients who did not experience the event, data were censored at their last visit before 30 June 2005 ( ) or at the initiation of treatment, n p 93 regardless of the reason for initiation ( ). Statistical comn p 14 parisons were based on the nonparametric Wilcoxon test or Student's t test for continuous variables. Percentages were compared by using the x 2 test or Fisher's exact test. Relative hazards (RHs) of progression, according to baseline characteristics, were estimated using a Cox proportional hazards model, after checking that the assumption of proportionality held. The following characteristics were considered: age, sex, the presence or absence of symptoms, CD4 and CD8 cell counts, and plasma HIV RNA and HIV DNA levels at study enrollment. Variables associated with the risk of progression in univariate analysis ( ) were included in the final multivariate model. Data P ! .25 were analyzed using SAS software (SAS Institute).
RESULTS
Characteristics of the patients. Among the 552 patients enrolled in the PRIMO Cohort during the study period, 163 (30%) did not start receiving antiretroviral therapy р3 months after diagnosis. Table 1 shows the main characteristics of these 163 patients. The demographic characteristics and HIV exposure group distributions were similar in the treated and untreated groups. Untreated patients were less severely ill at baseline than were treated patients (20% vs. 10% were asymptomatic) and were enrolled later after the estimated date of infection (median time, 68 vs. 40 days). Compared with treated patients, untreated patients had higher CD4 cell counts (628 vs. 478 cells/mm 3 ) and lower plasma HIV RNA and HIV DNA levels (4.6 vs. 5.3 log 10 copies/mL and 3.2 vs. 3.4 log 10 copies/10 6 PBMCs, respectively). The proportion of untreated patients increased from 18% during 1996-2001 to 43% during 2002-2004 . Accordingly, untreated patients recruited during 2002-2004 were more severely ill at enrollment than were patients recruited during 1996-2001. Among untreated patients recruited in the periods 2002-2004 and 1996-2001 , the respective median HIV RNA levels were 4.8 and 4.3 log 10 copies/mL ( ), the respective CD4 cell P p .004 3 ). The median HIV RNA level was 5.0 log 10 copies/mL (range, 3.0-5.9 log 10 copies/mL) at the time of disease progression. The median time to progression among these 56 patients was 6.7 months after enrollment.
Overall, the median time to disease progression estimated from Kaplan-Meier curves was 42 months after enrollment. Estimates of the risk of progression were 16% at 6 months (95% CI, 10%-22%), 25% at 1 year (95% CI, 18%-32%), 34% at 2 years (95% CI, 25%-42%), and 42% at 3 years (95% CI, 32%-52%) (figure 1).
Twenty-one patients (38%) were "early progressors," because they had CD4 cell counts !350 cells/mm 3 at month 3. Of these patients, 16 had CD4 cell counts !350 cells/mm 3 at enrollment ( ) or at the month 1 visit ( ). n p 11 n p 5 Factors predictive of disease progression. At baseline, patients with disease progression had a significantly lower median CD4 cell count than did those without progression (455 vs. 738 cells/mm 3 ; ), and they also had a higher median P ! .0001 HIV RNA level (4.9 vs. 4.5 log 10 copies/mL;
) and a P p .03 higher median HIV DNA level (3.3 vs. 3 .0 log 10 copies/10 6 PBMCs;
). Age, sex, time since infection, clinical fea-P p .003 tures of primary HIV infection, and CD8 count did not influence the risk of progression. Kaplan-Meier estimates were then made for strata established according to different threshold values of laboratory parameters (figure 2). As shown in figure 2A , a CD4 cell count !500 cells/ mm 3 was associated with a 77% risk of progression at 2 years (95% CI, 62%-93%), compared with only 5% (95% CI, 0%-12%) when the CD4 cell count was 1750 cells/mm 3 . A HIV RNA level 15.0 log 10 copies/mL was associated with a 55% risk of progression at 2 years (95% CI, 37%-73%), compared with 8% (95% CI, 0%-17%) among patients with levels !4.0 log 10 copies/mL (figure 2B). An HIV DNA level 13.4 log 10 copies/ 10 6 PBMCs (corresponding to the 66th percentile value) was associated with a 62% risk of progression at 2 years (95% CI, 44%-80%), compared with 13% (95% CI, 2%-23%) among patients with values !2.9 log 10 copies/10 6 PBMCs (corresponding to the 33rd percentile value) (figure 2C). The significant prognostic value of these parameters persisted when cutoffs established according to the 33rd and 66th percentile of CD4 cell counts and HIV RNA were used.
Cox modeling was used to further quantify the impact of these 3 factors (table 2). The relative risks of progression were 1.95 per decrease in the CD4 cell count of 100 cells/mm 3 ( ), 1.70 per increase in the HIV RNA level of 1 log 10 P ! .0001 copy/mL ( ), and 4.03 per increase in the HIV DNA P p .0001 level of 1 log 10 copy/10 6 PBMCs ( ). P ! .0001 Table 2 shows the results of multivariate analysis including age, the baseline CD4 cell count, and baseline HIV RNA and HIV DNA levels. A low CD4 cell count and a high HIV DNA level remained independently associated with an increased risk of progression, with relative risks of 1.84 per decrease in the CD4 cell count of 100 cells/mm 3 ( ) and 2.73 per in-P ! .0001 crease in the HIV DNA level of 1 log 10 copy/10 6 PBMCs ( ). In contrast, HIV RNA was no longer associated P p .003 with the risk of disease progression. To better define the respective impacts of the CD4 cell count and HIV DNA level, we also made Kaplan-Meier estimates for patients with values greater than and less than the overall baseline median CD4 cell count (628 cells/mm 3 ); patients in each subgroup were further stratified according to the median HIV DNA level (3.2 log 10 copies/10 6 PBMCs). The risk of progression was very low when the CD4 cell count was 1628 cells/mm 3 , regardless of the HIV DNA level ( figure 3A) . When the CD4 cell count was р628 cells/mm 3 ( figure 3B ), a high HIV DNA level added significant weight to the predictive value of the CD4 cell count. The estimated risk of progression among these patients within the first 2 years ranged from 41% (95% CI, 21%-60%) among those with a HIV DNA level !3.2 log 10 copies/10 6 PBMCs to 83% (95% CI, 67%-99%) among those with higher HIV DNA levels (
, by log rank test). P p .006
DISCUSSION
An increasing proportion of patients enrolled in the French PRIMO Cohort do not start receiving antiretroviral treatment within 3 months after the diagnosis of primary HIV-1 infection. Here, we examined the risk of clinical and immunological progression among the 163 untreated patients recruited from November 1996 to October 2004. During the follow-up period, only 1 patient had an AIDS-related clinical event, whereas 34% of the patients experienced immunological progression, as defined by a CD4 cell count !350 cells/mm 3 . The prognostic value of CD4 cell count and HIV RNA level has been analyzed in untreated patients who have had HIV-1 seroconversion, but these studies were performed before the HAART era and rarely included patients who received a diagnosis at the time of primary infection, and progression was defined by either a clinical event or a CD4 cell count !200 cells/mm 3 [27] [28] [29] [30] . Because immediate treatment initiation is now considered to be optional for patients who receive diagnoses during acute HIV-1 infection, treatment is generally indicated when the CD4 cell count decreases to !350 cells/mm 3 [20, 21] . We therefore used this threshold value as an end point for the analysis of progression.
The very low rate of clinical progression is likely to be the result of early treatment initiation for patients with severe acute infection. In contrast, immunological progression was frequent, occurring in 34% of patients. The estimated risks of progression were 25%, 34%, and 42% at years 1, 2, and 3, respectivelyvalues close to those observed elsewhere during the natural course of HIV-1 infection [31] . These rates of progression are surprisingly high, because untreated patients generally had less severe primary infection than did treated patients. When the HIV RNA level reaches its plateau after seroconversion, its predictive value for progression to AIDS is well established [32] . In contrast, the prognostic value of HIV RNA level in the early phase of infection is more controversial [7, 28, [33] [34] [35] . This apparent discrepancy may be because of the strong variability of HIV RNA levels, a phenomenon that may undermine their predictive value [27] [28] [29] [30] [31] . In our study, the predictive value of HIV RNA level for immunological progression disappeared when the CD4 cell count and HIV DNA levels were taken into account.
The HIV DNA level in PBMCs provides an estimate of the cellular HIV reservoir, which is established soon after infection [36, 37] . We found that HIV DNA level was predictive of the risk of progression, independently of CD4 cell count and HIV RNA level. This is consistent with previous studies showing that HIV DNA level is an important predictor of CD4 cell loss, AIDS, and death, both in patients with recent or chronic infection [25, 37] .
As expected, we found that the baseline CD4 cell count was the most potent predictor of progression in patients with recent seroconversion. Among the 47 patients who had a CD4 cell count !500 cells/mm 3 during the first 3 months after enrollment, 77% had disease progression within 2 years. Very few patients who had a CD4 cell count !350 cells/mm 3 during primary HIV infection experienced a spontaneous increase thereafter. Conversely, patients whose CD4 cell counts were 1750 cells/mm 3 had only a 5% risk of progression at 2 years. The predictive value of the CD4 cell count has major significance for the therapeutic management of primary HIV-1-infected patients. In the PRIMO Cohort, treatment now tends to be withheld until the CD4 cell count decreases to 350 cells/ mm 3 . This treatment-sparing strategy is currently being compared with an initial short-course therapy in the Spartac trial, which is described on the Web site of The National Research Register (http://www.nrr.nhs.uk/ViewDocument.asp?IDp N0241121238). Our results suggest that patients with CD4 cell counts 1750 cells/mm 3 during acute infection should not be treated immediately, given the potential adverse effects of therapy. This may also apply to patients with CD4 cell counts of 500-750 cells/mm 3 , who have a 25% risk of progression within 2 years; however, the additive predictive value of HIV DNA level observed here may also be of assistance in the decisionmaking process. Finally, immediate treatment appears to be warranted for most patients with CD4 cell counts !500 cells/ mm 3 . This is particularly the case for patients with a high HIV DNA level and/or a CD4 cell count !350 cells/mm 3 during the first 3 months after diagnosis. It should be noted that patients with baseline CD4 cell counts !500 cells/mm 3 represented 47% of the PRIMO Cohort population.
This study underlines the fact that immunological status can worsen rapidly in the absence of early treatment during primary HIV infection, even in a selected population of patients with relatively mild acute symptoms. Such patients must receive close clinical and laboratory monitoring if it is decided to postpone treatment. In addition to the CD4 cell count, the HIV DNA level may be a useful tool for making decisions regarding by Jules Levin on July 11, 2013 http://cid.oxfordjournals.org/ Downloaded from the optimal time to prescribe treatment to a patient with primary HIV-1 infection.
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